While glucose-lowering therapy bears the potential of stopping disease progression in the compensation phase, the IL-1β bi-stable switch model suggests that a combined glucose-lowering and anti-inflammatory therapy is necessary to stop the loss of functional β-cell mass as well as hyperglycaemia progression in the overt T2D phase, and eventually reestablish the compensation phase. Here, IL1B is linked to type 2 diabetes mellitus.